mRNA and Next-Generation Vaccine Platforms for Pandemic Influenza Preparedness

Area of Science:

• Vaccinology
• Infectious Disease Epidemiology
• Biotechnology

Background:

• Pandemic influenza poses a significant global health and economic threat.
• Current influenza vaccine systems face limitations in production speed, strain selection, and flexibility.
• The COVID-19 pandemic highlighted the potential of rapid vaccine development using platform technologies.

Purpose of the Study:

• To examine how messenger RNA (mRNA) and other next-generation vaccine technologies can enhance pandemic influenza preparedness.
• To review evidence on platform speed, clinical performance, manufacturing, regulatory pathways, and global access for new vaccine technologies.
• To identify emerging scientific frontiers in vaccine design and delivery for influenza.

Main Methods:

• Review of lessons learned from the COVID-19 pandemic vaccine response.
• Analysis of recent Phase III clinical trial data for seasonal influenza mRNA vaccines.
• Examination of global preparedness initiatives, such as the 100 Days Mission.

Main Results:

• Messenger RNA (mRNA) vaccines demonstrated unprecedented speed and efficacy during the COVID-19 pandemic.
• Next-generation platforms show promise for faster development and adaptable manufacturing for influenza vaccines.
• Advancements in artificial intelligence for immunogen design and novel delivery systems are emerging.

Conclusions:

• Sustained investment in adaptable vaccine platforms is critical for improving global pandemic influenza readiness.
• Integrating advances in vaccine delivery, manufacturing, and data-driven design will bolster response capabilities.
• Next-generation vaccines are essential to mitigate the impact of future influenza pandemics.